• XAV-939: Rethinking Wnt/β-Catenin Modulation for Translation

  2026-06-11

  Discover how XAV-939 (NVP-XAV939) is redefining the toolkit for translational researchers targeting the Wnt/β-catenin pathway. This in-depth exploration integrates mechanistic insight, recent cross-disease validation, and strategic workflow guidance, offering a new blueprint for disease modeling in cancer, fibrosis, neuroinflammation, and bone biology.

• Piezo1-Mediated Mechanotransduction in DRG Axon Regeneration

  2026-06-10

  This study establishes the mechanosensitive ion channel Piezo1 as a key regulator of axon regrowth in dorsal root ganglion (DRG) neurons by linking substrate stiffness to cytoskeletal dynamics via a Ca2+-dependent signaling pathway. The findings highlight the importance of microenvironmental stiffness in peripheral nerve regeneration and inform experimental approaches to dissect actin-mediated processes.

• Chlorambucil: Applied Protocols for DNA Replication Inhibiti

  2026-06-10

  Chlorambucil, a nitrogen mustard alkylating agent, delivers reproducible DNA crosslinking and selective cytotoxicity in cancer research. This guide translates cutting-edge findings into actionable workflows, troubleshooting strategies, and evidence-driven protocol enhancements for maximum assay reliability.

• Rifampin in Research: Optimizing Protocols for Transcription

  2026-06-09

  Rifampin stands out as a gold-standard rifamycin antibiotic for dissecting bacterial transcription and resistance. This guide details actionable workflows, experimental parameters, and troubleshooting strategies to empower researchers using APExBIO's Rifampin in bacterial resistance and synthetic biology studies.

• Strategic Apoptosis Detection: Mechanistic Insight to Transl

  2026-06-09

  Explore the translational impact of mechanistic apoptosis detection, integrating evidence from Hippo kinase MST1/2 research with best practices for deploying the One-step TUNEL FITC Apoptosis Detection Kit. This article provides actionable guidance for researchers seeking robust, reproducible, and clinically relevant apoptosis assays across tissue sections and cultured cells, while contextualizing emerging molecular insights within the broader landscape of cancer and immune research.

• ω-Agatoxin IVA TFA: Precision Tool for Synaptic Transmission

  2026-06-08

  ω-Agatoxin IVA TFA, supplied by APExBIO, offers unrivaled specificity for dissecting Cav2.1-mediated synaptic transmission and neuroprotection in both in vitro and in vivo models. This article delivers actionable protocols, troubleshooting strategies, and insights from recent structural breakthroughs—empowering neuroscience labs to achieve reproducible, high-impact results.

• In Vitro Susceptibility of Canine Staphylococci to Novobioci

  2026-06-08

  This study systematically evaluated the in vitro susceptibility of methicillin-resistant and methicillin-susceptible staphylococci isolated from both healthy dogs and dogs with superficial pyoderma to novobiocin and mupirocin. The findings clarify the activity spectrum of novobiocin, an aminocoumarin antibiotic, against clinically relevant staphylococcal isolates and provide data for guiding antibacterial resistance research in veterinary dermatology.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-06-07

  The reference study identifies a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, notably compound 8c, demonstrating potent nanomolar activity, excellent selectivity, and favorable pharmacokinetics. These findings advance targeted modulation of mitochondrial energy metabolism, providing a promising scaffold for therapeutic development in metabolic, allergic, and oncological diseases.

• Applied Workflows for Leucomycin (Kitasamycin) in Antibacter

  2026-06-06

  Leucomycin (kitasamycin) is a robust macrolide antibiotic, ideal for translational inhibition studies and resistance mechanism characterization. This article translates foundational biosynthetic insights into practical protocols, troubleshooting strategies, and advanced workflow enhancements for antibacterial drug discovery.

• Homoharringtonine: Cytotoxic Alkaloid Innovations for Resear

  2026-06-05

  Homoharringtonine stands out as a cytotoxic alkaloid that bridges leukemia research and SARS-CoV-2 antiviral workflows through targeted protein synthesis inhibition. By leveraging its dual-domain potential, researchers can accelerate robust assay development and streamline troubleshooting with APExBIO’s trusted formulation.

• Angiotensin II–HIF-1α-HILPDA Axis Drives Radioresistance in

  2026-06-05

  This study elucidates how local angiotensin II fosters radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis through the HIF-1α-HILPDA signaling axis. The findings highlight new molecular targets for radiosensitization and offer mechanistic insights relevant for translational oncology research.

• Structural Variants of Cyclosporin and Mitochondrial Pore In

  2026-06-04

  This study systematically compares cyclosporin variants B–E, revealing how subtle changes in peptide backbone flexibility and residue composition impact their capacity to inhibit the mitochondrial permeability transition pore (MPTP). The findings underscore that only variants mimicking cyclosporin A’s precise conformation retain potent mitochondrial and immunosuppressive actions, informing both targeted drug development and experimental design.

• Bismuth Subsalicylate: Applied Workflows in GI Disorder Rese

  2026-06-04

  Bismuth Subsalicylate (1,3,2λ2-benzodioxabismin-4-one) empowers researchers to dissect inflammation pathways and membrane biology in gastrointestinal disorder models. This guide delivers actionable workflows and troubleshooting strategies, leveraging APExBIO’s high-purity reagent for reproducible, advanced discovery.

• Ademetionine (SAM): Precision Tools for Methylation Workflow

  2026-06-03

  Leverage S-Adenosylmethionine (Ademetionine) as a robust methyl donor for advanced methylation reactions in proteins and DNA. Discover protocol-driven insights, practical troubleshooting, and the latest plant methyltransferase findings to enhance your epigenetic, metabolic, and neuropharmacology research.

• Chenodeoxycholic Acid for FXR Activation in Renal Research

  2026-06-03

  Chenodeoxycholic Acid (CDCA) is a potent FXR agonist that enables precise dissection of cholesterol metabolism and renal protective signaling, now validated as a key modulator of the FXR-KLF11-JAK2/STAT3 axis in acute kidney injury models. This article translates recent mechanistic insights into actionable workflows, troubleshooting guidance, and advanced applications leveraging the unique properties of CDCA.

451 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page